Willingness of Saudi Adults to Receive a COVID-19 Vaccine Booster Dose

Author:

Alshahrani Najim Z.ORCID,Ridda Iman,Rashid HarunorORCID,Alzahrani Faris,Othman Lujain Mohammed Bin,Alzaydani Hassan Ali

Abstract

Background: COVID-19 vaccine booster dose hesitancy amongst the Saudi Arabia population is a concern. The objectives of the study were to explore the Saudi public’s willingness to receive a COVID-19 vaccine booster dose and identify the factors affecting their willingness. Methods: From December 2021 to March 2022, an online cross-sectional survey using an anonymous, structured, and self-administered questionnaire was conducted among members of the Saudi public aged ≥18 years who did not receive a COVID-19 vaccine booster dose. Results: Of the 2101 respondents, 86.8% expressed a willingness to receive a COVID-19 vaccine booster dose. Multiple logistic regression analysis showed that age (18 to 25 years) (adjusted odds ratio [aOR] = 2.54; 95% confidence interval [95% CI] = 1.14–5.74), being single (aOR = 2.85; 95% Cl = 1.42–5.72), and prior receipt of an influenza vaccine (aOR = 2.45; 95% Cl = 1.80–3.34) were significantly associated with participants’ willingness to receive the COVID-19 vaccine booster dose. Having a bachelor’s degree or above (aOR = 0.95; 95% CI = 0.81–0.99) and not following COVID-19 news (aOR = 0.70; 95% CI = 0.52–0.89) were associated with a significant likelihood of having no intention to receive the COVID-19 vaccine boosters. Conclusions: Most Saudi people were willing to have the COVID-19 vaccine booster dose, with age and prior influenza vaccination as the predictors; paradoxically, a university-level qualification was a barrier.

Publisher

MDPI AG

Subject

Management, Monitoring, Policy and Law,Renewable Energy, Sustainability and the Environment,Geography, Planning and Development,Building and Construction

Reference36 articles.

1. Estimate and determinants of SARS-CoV-2 RNA clearance time among non-severe COVID-19 patients;Aljunaid;J. Fam. Med. Prim. Care,2022

2. (2022, November 29). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/.

3. Alkhormi, A.H., Mahfouz, M.S., Alshahrani, N.Z., Hummadi, A., Hakami, W.A., Alattas, D.H., Alhafaf, H.Q., Kardly, L.E., and Mashhoor, M.A. (2022). Psychological Health and Diabetes Self-Management among Patients with Type 2 Diabetes during COVID-19 in the Southwest of Saudi Arabia. Medicina, 58.

4. Launching COVID-19 vaccination in Saudi Arabia: Lessons learned, and the way forward;Assiri;Travel Med. Infect. Dis.,2021

5. Saudi Press Agency (2022, May 21). SFDA Approves Registration of Pfizer-BioNTech COVID-19 Vaccine, Available online: https://www.spa.gov.sa/viewfullstory.php?lang=en&newsid=2166947.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3